PLDscreen - a fast screen for unparalleled prediction of risk for drug-induced phospholipidosis

Phospholipidosis (PLD), the accumulation of phospholipids in tissues such as lungs, kidneys and liver, has been recognized to represent a potential causative process for a number of serious side effects, particularly for drugs intended for long term usage by the patients. Consequently, it is desirable to identify potential PLD inducing compounds at an early drug development stage, such as lead optimization.

The reason for PLD is believed to be the formation of drug-phospholipid complexes, which cannot be metabolized by phospholipid-degrading enzymes, phospholipases.

Kibron PLDscreen is a robust in vitro HTS assay which measures directly the strength of drug-phospholipid interaction. More specifically, it detects the drug-induced shift in the critical micelle concentration (CMC) for a phospholipid, measured using our Delta-8 surface tension plate reader. PLDscreen predicts with unparalleled accuracy the ability of compounds to induce PLD. This proprietary assay allows for high throughput screening of molecules with minimal compound consumption, hundreds of compounds in a single working day!